Clinical trials: Clear Cell Kidney Cancer
Renal Cell Carcinoma, Clear-cell Renal Cell Carcinoma
Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer
This is a correlative (lab-based) study aiming to identify protein markers in urine extracellular vesicles (EVs) that can be used to develop non-invasive molecular tests for patients with renal cell carcinoma (RCC).
- Conditions
- Renal Cell Carcinoma, Clear-cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma
- Trial name
- NCT07243067
- Testing
- Proteomic profiling of urinary EVs, Blood sample collection
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Mayo Clinic
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib for patients who received anti-PD-1 or anti-PD-L1 therapy as part of the…
- Trial name
- NCT07011719
- Testing
- Casdatifan, Cabozantinib
- Where
- 191 sites in United States, Argentina and 15 more
- Volunteers
- 720 people
- Sponsor
- Arcus Biosciences, Inc.
Renal Cell Carcinoma
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)
This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory renal cell carcinoma.
- Trial name
- NCT04438083
- Testing
- CTX130
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 19 people
- Sponsor
- CRISPR Therapeutics AG
Kidney Cancer
Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00057889
- Testing
- ipilimumab
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Clear-cell Metastatic Renal Cell Carcinoma
A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
A-PREDICT is a study of axitinib in patients with metastatic renal cell carcinoma unsuitable for nephrectomy (as judged by the treating clinician) to evaluate efficacy, safety, toxicity and changes in biomarkers during therapy.
- Trial name
- A-PREDICT (NCT01693822)
- Testing
- Axitinib
- Where
- 11 sites in United Kingdom
- Volunteers
- 65 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Kidney Cancer
Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer
RATIONALE: Combinations of biological substances in denileukin diftitox may be able to carry tumor-killing substances directly to kidney cancer cells. Interleukin-2 may stimulate the white blood cells to kill kidney cancer cells.
- Trial name
- NCT00278369
- Testing
- aldesleukin, denileukin diftitox
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Non-Clear Cell Renal Cell Carcinoma
Personalized ctDNA Monitoring for Predicting Immunotherapy Outcomes in Advanced Non-Clear Cell Renal Cell Carcinoma
This is a prospective, non-interventional observational cohort study evaluating the clinical utility of patient-specific circulating tumor DNA (ctDNA) monitoring in patients with advanced non-clear cell renal cell carcinoma…
- Trial name
- NCT07776483
- Testing
- Patient-Specific Tumor-Informed ctDNA Monitoring
- Volunteers
- 67 people
- Sponsor
- West China Hospital
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
This phase II trial compares the safety and effectiveness of 89Zr-DFO-GmAb positron emission tomography (PET)/computed tomography (CT) compared to contrast-enhanced CT after surgery in detecting clear cell renal cell cancer that…
- Conditions
- Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer
- Trial name
- NCT06447103
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC)…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Urothelial Carcinoma (UC)
- Trial name
- NCT05706129
- Testing
- [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452
- Where
- 10 sites in Australia, France
- Volunteers
- 270 people
- Sponsor
- Lumara Bio Oncologics GmbH
Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
This phase I/II trial studies the side effects and best dose of sorafenib tosylate and bevacizumab and to see how well they work in treating patients with advanced kidney cancer.
- Conditions
- Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma
- Trial name
- NCT00126503
- Testing
- Bevacizumab, Sorafenib Tosylate, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Myeloproliferative Disorders, Kidney Cancer
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00787761
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northside Hospital, Inc.
Solid Tumor, Clear Cell Renal Cell Carcinoma
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the poly adenosine diphosphate ribose…
- Conditions
- Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
- Trial name
- NCT03875313
- Testing
- CB-839, Talazoparib
- Where
- 9 sites in United States
- Volunteers
- 33 people
- Sponsor
- Calithera Biosciences, Inc
Clear Cell Renal Cell Carcinoma and Glioblastoma
Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma
A prospective, open-label, phase 1 study. This clinical trial aims to evaluate the diagnostic value of 68Ga-XT771, a CAIX/CAXII protein-specific probe, in PET/CT imaging for patients with clear cell renal cell carcinoma and…
- Trial name
- NCT07067905
- Testing
- 68Ga-XT771
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Chinese PLA General Hospital
Neuroblastoma, Medulloblastoma
Molecular-Guided Therapy for Childhood Cancer
The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup.
- Conditions
- Neuroblastoma, Medulloblastoma, Glioma, Ependymoma
- Trial name
- NCT02162732
- Testing
- Guided Therapy
- Where
- 19 sites in United States, Lebanon
- Volunteers
- 186 people
- Sponsor
- Giselle Sholler
Metastatic Renal Cell Carcinoma
Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer
The objective of this study is to assess the progression-free survival, of patients who receive rotations of sunitinib and everolimus versus patients who receive sunitinib as a first line treatment followed by everolimus when…
- Trial name
- SUNRISES (NCT01784978)
- Testing
- Sunitinib, Everolimus
- Where
- 10 sites in France, Greece and 1 more
- Volunteers
- 41 people
- Sponsor
- Associació per a la Recerca Oncologica, Spain
Clear Cell Renal Cell Carcinoma
CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
The primary objective of this study is to compare the progression-free survival (PFS) of participants treated with telaglenastat and everolimus versus placebo and everolimus for advanced or metastatic clear cell renal cell…
- Trial name
- ENTRATA (NCT03163667)
- Testing
- CB-839, everolimus
- Where
- 38 sites in United States
- Volunteers
- 69 people
- Sponsor
- Calithera Biosciences, Inc
Renal Cell Carcinoma, Pulmonary Metastases
Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)
The aim ist to identify biomarkers in the blood, to indicate early response or early treatment resistance.
- Trial name
- SMAT (NCT01216371)
- Testing
- Sunitinib
- Where
- 11 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Association of Urologic Oncology (AUO)
Renal Cancer
Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Usually, doctors monitor kidney cancer with CT scans to measure the size of tumors. Sometimes, even when a drug is working, it can take several months before the effects are seen on a regular CT scan.
- Trial name
- NCT01582204
- Testing
- 124IcG250
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Clear Cell Renal Carcinoma
Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
The combination of immune checkpoint inhibitors (ICIs) plus angiogenesis inhibitors has demonstrated significant anti-tumor activity in certain cancer.
- Trial name
- NCT05220267
- Testing
- Anlotinib plus Sintilimab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Adenocarcinoma
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.
- Conditions
- Carcinoma, Adenocarcinoma, Renal Cell, Nephroid Carcinoma
- Trial name
- NCT00719264
- Testing
- RAD001(everolimus), interferon alfa-2a, bevacizumab
- Where
- 109 sites in United States, Belgium and 19 more
- Volunteers
- 365 people
- Sponsor
- Novartis Pharmaceuticals